Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients

Author(s): Seyed Mostafa Seyedmardani*, Mir Amir Aghdashi , Shaida Soltani and Golshan Kamali Zonouz

Volume 18, Issue 1, 2022

Published on: 07 December, 2021

Page: [48 - 57] Pages: 10

DOI: 10.2174/1573397117666211012105611

Price: $65

Abstract

Background/Aims: Raynaud's phenomenon by episodically reversible constriction of the arteries in the fingers and toes causes pain, numbness, sores, and gangrene. However, the treatment of Raynaud's phenomenon is one of the clinical issues. Recent studies have shown that botulinum toxin is considered a potential and effective therapeutic option for improving finger blood circulation in patients with Raynaud's syndrome. In this study, we sought to investigate the therapeutic effect of botulinum toxin type A on exacerbated Raynaud's phenomenon in patients with scleroderma.

Methods: In this prospective study, 11 patients with systemic scleroderma who were referred due to aggravated Raynaud's were included. For all patients, questionnaires were filled up, and physical examination was performed separately for both treatment and control hands, and then similar volumes of botulinum toxin type A (Botox) and normal saline were randomly injected.

Results: The results showed that there was a significant difference in Raynaud's score (P = 0.001), Quick-Dash score (P = 0.01), Mc-Cabe cold score (P = 0.003), the mean frequency of recurrences arracks (P = 0.01), pain (0.005) (P = 0), skin color (P = 0.01), and duration of Raynaud's phenomenon (P = 0.006) between the intervention and control groups after two months.

Conclusion: Following Botox injection, a significant improvement in terms of various Raynaud's parameters as well as the clinical manifestations was observed in the intervention group. Together, botulinum toxin type A could retrieve the hand function, the cold sensitivity, and the painful feeling caused by Raynaud's syndrome.

Keywords: Botox, botulinum toxin A, raynaud's syndrome, scleroderma, parameters, therapeutic intervention.

« Previous Next »
[1]
Bakst R, Merola JF, Franks AG Jr, Sanchez M. Raynaud’s phenomenon: pathogenesis and management. J Am Acad Dermatol 2008; 59(4): 633-53.
[http://dx.doi.org/10.1016/j.jaad.2008.06.004] [PMID: 18656283]
[2]
Neumeister MW. Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg Am 2010; 35(12): 2085-92.
[http://dx.doi.org/10.1016/j.jhsa.2010.09.019] [PMID: 21134617]
[3]
Morrisroe K, Stevens W, Sahhar J, et al. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden.Arthritis Res Ther 2019; 21(1): 299.
[http://dx.doi.org/10.1186/s13075-019-2080-y] [PMID: 31870459]
[4]
Iorio ML, Masden DL, Higgins JP. Seminars in arthritis and rheumatism. In: Botulinum toxin A treatment of Raynaud’s phenomenon: A review. Elsevier 2012; pp. 599-603.
[5]
Cappelli L, Wigley FM. Management of Raynaud phenomenon and digital ulcers in scleroderma. Rheumatic Dis Clin 2015; 41(3): 419-38.
[http://dx.doi.org/10.1016/j.rdc.2015.04.005] [PMID: 26210127]
[6]
Chiou G, Crowe C, Suarez P, Chung L, Curtin C, Chang J. Digital sympathectomy in patients with scleroderma: An overview of the practice and referral patterns and perceptions of rheumatologists. Ann Plast Surg 2015; 75(6): 637-43.
[http://dx.doi.org/10.1097/SAP.0000000000000614] [PMID: 26418780]
[7]
Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: A randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol 2017; 69(8): 1661-9.
[http://dx.doi.org/10.1002/art.40123] [PMID: 28426903]
[8]
Wigley FM. Clinical practice. Raynaud’s Phenomenon. N Engl J Med 2002; 347(13): 1001-8.
[http://dx.doi.org/10.1056/NEJMcp013013] [PMID: 12324557]
[9]
Stone AV, Koman LA, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: A potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am 2012; 37(4): 795-802.
[http://dx.doi.org/10.1016/j.jhsa.2012.01.021] [PMID: 22386546]
[10]
Van Beek AL, Lim PK, Gear AJL, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 2007; 119(1): 217-26.
[http://dx.doi.org/10.1097/01.prs.0000244860.00674.57] [PMID: 17255677]
[11]
Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud’s phenomenon: A pilot study. Eur J Clin Invest 2004; 34(4): 312-3.
[http://dx.doi.org/10.1111/j.1365-2362.2004.01324.x] [PMID: 15086364]
[12]
Serri J, Legré R, Veit V, Guardia C, Gay AM. Botulinum toxin type A contribution in the treatment of Raynaud’s phenomenon due to systemic sclerosis. Ann Chir Plast Esthet 2013; 58(6): 658-62.
[http://dx.doi.org/10.1016/j.anplas.2011.11.001] [PMID: 22204894]
[13]
Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma. J Hand Surg Eur Vol 2014; 39(8): 876-80.
[http://dx.doi.org/10.1177/1753193413516242] [PMID: 24369360]
[14]
Neumeister MW, Chambers CB, Herron MS, et al. Botox therapy for ischemic digits. Plast Reconstr Surg 2009; 124(1): 191-201.
[http://dx.doi.org/10.1097/PRS.0b013e3181a80576] [PMID: 19568080]
[15]
Wigley FM, Flavahan NA. Raynaud’s Phenomenon. N Engl J Med 2016; 375(6): 556-65.
[http://dx.doi.org/10.1056/NEJMra1507638] [PMID: 27509103]
[16]
Motegi S-I, Uehara A, Yamada K, et al. Efficacy of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol 2017; 97(7): 843-50.
[http://dx.doi.org/10.2340/00015555-2665] [PMID: 28358168]
[17]
Webb KN, Berry NN, Bueno RA, Neumeister MW. Abstract 5: A 28-Day Prospective, Randomized, Double-Blind, Placebo Controlled Clinical Trial of Botulinum Toxin Type A for Raynaud’s Phenomen. Plast Reconstr Surg 2014; 133(3): 13.
[http://dx.doi.org/10.1097/01.prs.0000444918.38206.74] [PMID: 25942116]
[18]
Dhaliwal K, Griffin M, Denton C P, Butler P E. The novel use of botulinum toxin A for the treatment of Raynaud’s phenomenon in the toes. Case Reports 2018; 2018
[19]
Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Seminars in arthritis and rheumatism. Elsevier 2016; pp. 115-23.
[20]
Hummers LK, Wigley FM. Management of Raynaud’s phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 2003; 29(2): 293-313.
[http://dx.doi.org/10.1016/S0889-857X(03)00019-X] [PMID: 12841296]
[21]
Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study. J Dermatol 2016; 43(1): 56-62.
[http://dx.doi.org/10.1111/1346-8138.13030] [PMID: 26173902]
[22]
Serri J, Legre R, Veit V, Guardia C, Gay AM. Intérêt de la toxine botulinique de type A dans le traitement des syndromes de Raynaud sévères secondaires à la sclérodermie systémique Annales de Chirurgie Plastique Esthétique. Elsevier 2013; pp. 658-62.

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy